Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
154.4 EUR | +0.16% | +2.73% | +7.15% |
May. 08 | MERCK KGAA : UBS reiterates its Buy rating | ZD |
May. 07 | MERCK KGAA : Gets a Buy rating from JP Morgan | ZD |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's enterprise value to sales, at 3.46 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.15% | 72.03B | A | ||
-10.86% | 5.14B | A- | ||
+46.43% | 4.6B | - | ||
+5.38% | 3.96B | B- | ||
-16.20% | 2.5B | C- | ||
+20.84% | 2.43B | B | ||
-26.20% | 2.32B | - | ||
+19.92% | 2.18B | - | - | |
+8.15% | 1.72B | D+ | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA